Shiqi Xu
RESEARCH:
My research is focused on developing specific inhibitors for SENP family members to fight cancer. SUMOylation is a reversible post-translational modification that involves the modification of substrate proteins by SUMO proteins in an ATP-dependent enzyme-catalyzed cascade reaction, similar to ubiquitination. Different types of SUMOylation exist in cells, including monoSUMOylation, multi-monoSUMOylation and polySUMOylation, all of which can be dissociated by proteases from the SENP family. Recently, some SENP family members emerged as potential anti-tumor targets because they are highly expressed in a variety of tumor cells and associated with many vital activities, including cell circulation and cell survival gene expression. In my PhD, I will synthesize and test compounds that were identified to inhibit SENPs by virtual screening. Compounds that show good potential towards SENP inhibition will be optimized for their potency and selectivity by medicinal chemistry efforts. In addition, I will conduct high-throughput screening to identify new lead compounds.
CUrRICULUM VITAE:
I obtained my master's degree in medicinal chemistry from Peking Union Medical College in July 2023. During my master's, my research project was the design, synthesis and target confirmation of novel triazole antitumor inhibitors. During this period, I synthesized a series of compounds with anti-tumor activity and found their targets using ABPP technology. In October 2024, I started my PhD in the Cell and Chemical Biology department under the supervision of Alfred Vertegaal and Paul Geurink.
Publications
-
Pairs of thiol-substituted 1,2,4-triazole-based isomeric covalent inhibitors with tunable reactivity and selectivity
Shiqi Xu, Zi Ye, Shuang Shang, Fengge Wang, Huan Zhang, Lianguo Chen, Hao Lin, Chen Chen, Fang Hua, Chong-Jing Zhang.
Chinese Chemical Letters. 2024, 35(7):109034
-
Synthesis of a novel series of amino acid prodrugs based on tegafur and evaluation of their antitumor activity.
Shiqi Xu, Liyan Zhu, Chao Hao, Wenqian Liu, Chenglong Chen, Yongyi Chen, Aiqin Liu.
Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 743-753.
-
Stereochemistry and antimalarial activity of C-10 carba analogues of artemisinin.
Fengge Wang, Shiqi Xu, Chen Chen, Chunyan Wei, Chong-Jing Zhang*,
Bioorganic & Medicinal Chemistry Letters, 2023, 93, 129414.
